SCHEMBL6690356

SCHEMBL6690356

COc1ccc(C2=NN(CCc3ccc(NC(=O)c4ccncc4)cc3)C(=O)SC2)cc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ POLB P06746 3/20 0.47
▸ FLT1 P17948 1/20 0.47
▸ KDR P35968 1/20 0.47
▸ PDE4B Q07343 2/20 0.47
▸ MET P08581 1/20 0.47
▸ PDE4A P27815 1/20 0.47
▸ PDE4C Q08493 1/20 0.47
▸ PDE4D Q08499 1/20 0.47
▸ PDE3B Q13370 1/20 0.47
▸ PDE3A Q14432 1/20 0.47
▸ NAMPT P43490 1/20 0.47
▸ MEN1 O00255 4/20 0.46
▸ KMT2A Q03164 4/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6687267 0.91 PDE4B (0.53) LMNASMN1; SMN2MAPK1HTTL3MBTL1
SCHEMBL147713 0.90 ABCG2 (0.57) LMNASMN1; SMN2MAPK1HTTPOLB
SCHEMBL6655224 0.88 PDE4B (0.48) LMNASMN1; SMN2L3MBTL1POLBFLT1
SCHEMBL7798666 0.88 PDE4B (0.54) LMNASMN1; SMN2MAPK1HTTPOLB
SCHEMBL7801804 0.88 PDE4B (0.50) LMNASMN1; SMN2MAPK1HTTPOLB
SCHEMBL7792970 0.88 CYP1A2 (0.55) LMNASMN1; SMN2MAPK1HTTPDE4B
SCHEMBL6677128 0.87 PDE4B (0.56) LMNASMN1; SMN2MAPK1HTTL3MBTL1
SCHEMBL6654591 0.87 ABCG2 (0.48) LMNASMN1; SMN2POLBFLT1KDR
SCHEMBL6842268 0.87 PDE4B (0.46) LMNASMN1; SMN2MAPK1HTTL3MBTL1
SCHEMBL6844037 0.87 SMN1; SMN2 (0.52) LMNASMN1; SMN2L3MBTL1POLBPDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 — — US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 — — EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 — — WO disclosed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 — — EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 — — US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B LMNA 2603/4885SMN1; SMN2 2642/4885MAPK1 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback